This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 Jun 22;381(9884):2141-3.

doi: 10.1016/S0140-6736(13)60065-3. Epub 2013 Apr 4.

Anti-interleukin-2 receptor alpha for multiple sclerosis?

Shiv Saidha¹, Peter A Calabresi

Affiliations

PMID: 23562008
DOI: 10.1016/S0140-6736(13)60065-3

Comment

Anti-interleukin-2 receptor alpha for multiple sclerosis?

Shiv Saidha et al. Lancet. 2013.

. 2013 Jun 22;381(9884):2141-3.

doi: 10.1016/S0140-6736(13)60065-3. Epub 2013 Apr 4.

Authors

Shiv Saidha¹, Peter A Calabresi

Affiliation

¹ Department of Neurology, Beaumont University Hospital, Dublin, Ireland.

PMID: 23562008
DOI: 10.1016/S0140-6736(13)60065-3

No abstract available

PubMed Disclaimer

Comment on

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G; SELECT study investigators. Gold R, et al. Lancet. 2013 Jun 22;381(9884):2167-75. doi: 10.1016/S0140-6736(12)62190-4. Epub 2013 Apr 4. Lancet. 2013. PMID: 23562009 Clinical Trial.

Similar articles

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G; SELECT study investigators. Gold R, et al. Lancet. 2013 Jun 22;381(9884):2167-75. doi: 10.1016/S0140-6736(12)62190-4. Epub 2013 Apr 4. Lancet. 2013. PMID: 23562009 Clinical Trial.
Daclizumab (Zinbryta) for multiple sclerosis.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2016 Sep 12;58(1503):117-9. Med Lett Drugs Ther. 2016. PMID: 27603962 No abstract available.
Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis.
Patti F, Chisari CG, D'Amico E, Zappia M. Patti F, et al. Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):341-352. doi: 10.1080/17425255.2018.1432594. Epub 2018 Jan 30. Expert Opin Drug Metab Toxicol. 2018. PMID: 29363337 Review.
Journal club: Intrathecal effects of daclizumab treatment of multiple sclerosis.
Schneider R, Arbour N. Schneider R, et al. Neurology. 2012 May 29;78(22):e131-3. doi: 10.1212/WNL.0b013e31825830e3. Neurology. 2012. PMID: 22641406 Clinical Trial. No abstract available.
▼ Daclizumab for MS.
[No authors listed] [No authors listed] Drug Ther Bull. 2017 Feb;55(2):18-21. doi: 10.1136/dtb.2017.2.0454. Drug Ther Bull. 2017. PMID: 28183723 Review.

See all similar articles

Cited by

Integration of Genetic and Immune Infiltration Insights into Data Mining of Multiple Sclerosis Pathogenesis.
Zhang X, Song Y, Chen X, Zhuang X, Wei Z, Yi L. Zhang X, et al. Comput Intell Neurosci. 2022 Jun 27;2022:1661334. doi: 10.1155/2022/1661334. eCollection 2022. Comput Intell Neurosci. 2022. PMID: 35795733 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations